These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Henness S; Wigley FM Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543 [TBL] [Abstract][Full Text] [Related]
23. Raynaud's phenomenon and Raynaud's disease definition of Raynaud's phenomenon. Pratesi F; Corsi C; Deidda C; Nuti A Schweiz Rundsch Med Prax; 1976 Nov; 65(44):1368-70. PubMed ID: 1005332 [No Abstract] [Full Text] [Related]
24. Raynaud's Phenomenon: treatment of a severe case with biofeedback. Adair JR; Theobald DE J Indiana State Med Assoc; 1978 Oct; 71(10):990-3. PubMed ID: 701835 [No Abstract] [Full Text] [Related]
25. Generalized scleroderma with Raynaud's phenomena. Report of a case. Elmostehy MR; Bissada NF Egypt Dent J; 1970 Jan; 16(1):83-8. PubMed ID: 5268450 [No Abstract] [Full Text] [Related]
26. [Raynaud's disease, acrocyanosis and scleroderma in the menopause]. Lo Stumbo F; Banchelli A Minerva Ginecol; 1965 Nov; 17(21):1034-43. PubMed ID: 5880755 [No Abstract] [Full Text] [Related]
27. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. Surwit RS; Gilgor RS; Allen LM; Duvic M Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665 [TBL] [Abstract][Full Text] [Related]
28. Interstitial calcinosis and scleroderma associated with rheumatoid arthritis and Raynaud's disease.5A case report. Sherman BD J Am Podiatry Assoc; 1968 Feb; 58(2):68-71. PubMed ID: 5636488 [No Abstract] [Full Text] [Related]